GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

CNBC

12:27 PM | Friday | Aug 14, 2026

news photo
Loading...

A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.

Read full article redirect
12:27 PM | Friday | Aug 14, 2026

Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

CNBC

A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.

Read full article arrow
NEW News Thumbnail
4:01 AM | Tuesday | Aug 11, 2026

First Bank & Trust Lowers Stock Position in Gilead Sciences, Inc. $GILD

Defense World

First Bank and Trust decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 22.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,831 shares of the biopharmaceutical company's stock after selling 6,178 shares during the quarter.

Read full article arrow
News Thumbnail
9:16 AM | Monday | Aug 10, 2026

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Seeking Alpha

Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter.
On the other hand, Livdelzi, a PPARฮด agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.

Read full article arrow
News Thumbnail
11:03 AM | Friday | Aug 7, 2026

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Zacks Investment Research

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.

Read full article arrow
News Thumbnail
11:31 AM | Thursday | Aug 6, 2026

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

Seeking Alpha

Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and raised guidance. GILD's HIV portfolio, especially Biktarvy and Descovy, continues to drive sales, but revenue concentration poses mid-2030s patent cliff risk. Recent acquisitions inflated Q2 operating losses, yet free cash flow surged to $3.4B, and debt remains manageable relative to cash generation.

Read full article arrow
News Thumbnail
12:26 PM | Wednesday | Aug 5, 2026

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

Zacks Investment Research

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Read full article arrow
News Thumbnail
12:06 AM | Wednesday | Aug 5, 2026

Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV Growth Accelerates, and Strategic Pipeline Advances

GuruFocus

Total Product Sales (excluding Veklury): $7.6 billion, up 10% year-over-year.Total Product Sales (including Veklury): $7.6 billion, up 8% year-over-year.HIV Sal

Read full article arrow
News Thumbnail
10:00 PM | Tuesday | Aug 4, 2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

GuruFocus

Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have bee

Read full article arrow
News Thumbnail
9:41 PM | Tuesday | Aug 4, 2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea.

Read full article arrow
News Thumbnail
9:20 PM | Tuesday | Aug 4, 2026

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Seeking Alpha

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Read full article arrow
News Thumbnail